Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...

MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...

US pharma giant Merck & Co and China’s Jiangsu Hengrui Pharmaceuticals have entered into an exclusive license agreement for ...